The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J05 | Antivirals for systemic use | |
3
|
J05A | Direct acting antivirals | |
4
|
J05AJ | Integrase inhibitors | |
5
|
J05AJ01 | Raltegravir |
| Active Ingredient |
|---|
|
Raltegravir is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus (HIV-1). Raltegravir inhibits the catalytic activity of integrase, an HIV-encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of the HIV genome into the host cell genome. |
| Document | Type | Information Source | |
|---|---|---|---|
| ISENTRESS Chewable tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ISENTRESS Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ISENTRESS Granules for oral suspension | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.